[Form 4] Sight Sciences, Inc. Insider Trading Activity

Rhea-AI Filing Summary

Sight Sciences reported that Brenton Taylor, EVP of Operations & R&D and a company officer, received a grant of 25,840 restricted stock units (RSUs) on September 2, 2025 under the 2021 Incentive Award Plan. Each RSU represents a contingent right to one share of common stock and the grant is described as equal to approximately $100,000 of common stock based on the closing price on the grant date. The RSUs vest in 16 equal quarterly installments beginning September 30, 2025 and continuing through June 30, 2029, subject to continued service; the RSUs have no expiration date. After the grant, the reporting person beneficially owns 185,840 shares (direct).

Positive

• 25,840 RSUs granted to EVP Brenton Taylor, signaling retention alignment
• Vesting spread over 16 quarterly installments from Sept 30, 2025 to June 30, 2029, promoting multi-year retention
• Grant valued at approximately $100,000 based on closing price on grant date
• Reporting person beneficial ownership increased to 185,840 shares (direct)

Negative

• None.

Insights

Financial Analyst

TL;DR: A routine, time‑based executive RSU grant worth about $100k that vests over four years; modest near‑term dilution and aligns pay with retention.

The grant of 25,840 RSUs increases the reporting person's direct beneficial ownership to 185,840 shares and is structured to vest in 16 quarterly installments through mid‑2029, which supports retention incentives without immediate cash outlay. The award size (~$100,000) is modest relative to typical executive compensation packages and conveys alignment with shareholder outcomes because conversion to shares is contingent on continued service. There are no performance vesting conditions or exercise price, and the RSUs have no expiration date.

Corporate Governance Expert

TL;DR: Standard service‑based equity grant consistent with typical governance practices to encourage multi‑year retention.

The RSU structure—time‑based vesting over 16 quarters and conversion to one share per RSU—reflects a standard retention instrument. The filing clearly discloses the grant amount, vesting schedule, and that vesting is conditioned on continued service. The disclosure does not indicate performance conditions, accelerated vesting, or special transfer arrangements. As filed, the transaction appears procedurally compliant and routine for an officer-level award.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Taylor Brenton

(Last) (First) (Middle)

C/O SIGHT SCIENCES, INC.

4040 CAMPBELL AVE., SUITE 100

(Street)

MENLO PARK CA 94025

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Sight Sciences, Inc. [ SGHT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	EVP, Operations & R&D

3. Date of Earliest Transaction (Month/Day/Year)
09/02/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	09/02/2025		A		25,840(1)	A	$0.00	185,840	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Reflects a grant of restricted stock units ("RSUs") made to the Reporting Person under the Issuer's 2021 Incentive Award Plan. The RSUs vest in 16 equal quarterly installments commencing September 30, 2025 and continuing through June 30, 2029, subject to the Reporting Person's continued service to the Issuer through each vesting date. Each RSU represents a contingent right to receive one share of the Issuer's common stock, par value $0.001 per share ("Common Stock"). The number of RSUs granted is equal to approximately $100,000 of shares of Common Stock as determined by the closing price on the grant date, September 2, 2025. The RSUs have no expiration date.

	/s/ Jeremy Hayden, Attorney-in-Fact for Brenton Taylor	09/03/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did Brenton Taylor receive according to the Form 4 for SGHT?

The Form 4 reports a grant of 25,840 restricted stock units (RSUs) on September 2, 2025 under the 2021 Incentive Award Plan.

How are the RSUs structured and when do they vest?

The RSUs vest in 16 equal quarterly installments beginning September 30, 2025 and continuing through June 30, 2029, subject to continued service.

What is the reported value of the RSU grant?

The Form 4 states the number of RSUs equals approximately $100,000 of common stock as determined by the closing price on the grant date.

How many shares does the reporting person own after the grant?

After the reported transaction the reporting person beneficially owns 185,840 shares (direct).

Do the RSUs have an expiration date or performance conditions?

The RSUs have no expiration date and are described as time‑based vesting; no performance conditions are disclosed in the filing.